Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Shanghai Jiao Tong University School of Medicine is the lead sponsor of 77 current clinical trials in our China register. 50 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Pertuzumab, Pyrotinib and Trastuzumab. The most-studied condition is Breast Cancer.

ClinicalTrials.gov trials by status

Recruiting5065%
Not yet open1317%
Active, closed1216%
By invitation23%

Trials by phase

Observational2330%
Phase 21621%
Not applicable1418%
Phase 368%
Phase EARLY_PHASE168%
Phase 434%
Phase 1/234%
Phase 2/334%
Phase 134%

Clinical trials sponsored by Shanghai Jiao Tong University School of Medicine

77 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Autoimmune Hepatitis Cohort in China NCT05785793 · Autoimmune Hepatitis	Observational	Recruiting	2023-02	China
Chemotherapy CLAGE-Ven Sequential With Reduced Intensity Conditioning for Refractory Acute Myelodi Leukemia NCT05870995 · ClinicalTrials.gov ↗ · Refractory Leukemia	Phase 2	Recruiting	2023-02	China
Neoadjuvant Pyrotinib-to-pertuzumab in HER2+ eBC NCT07797218 · ClinicalTrials.gov ↗ · Breast Cancer Early Stage Breast Cancer (Stage 1-3) Drugs: Docetaxel, Pertuzumab, Pyrotinib	Phase 3	Recruiting	2026-07	China
6-year Follow-up Data After the Berberine Intervention Trial NCT06629051 · ClinicalTrials.gov ↗ · Colorectal Adenoma, Colorectal Cancer Control and Prevention, Colorectal Polyps	Observational	Recruiting	2024-10	China
Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA NCT04183712 · ClinicalTrials.gov ↗ · Gallbladder Carcinoma Drugs: Afatinib, Gemcitabine and oxaliplatin	Phase 2	Recruiting	2020-06	China
Epidemiological Investigation of Helicobacter Pylori-infected Patients and the Effect of Eradication Treatment on Dyspepsia Symptoms NCT06422052 · ClinicalTrials.gov ↗ · Helicobacter Pylori Infection, Dyspepsia	Observational	Recruiting	2024-03	China
Evaluation of the Safety and Efficacy of BBM-D101 to Treat Patients with Duchenne Muscular Dystrophy NCT06641895 · ClinicalTrials.gov ↗ · Duchenne Muscular Dystrophy (DMD)	Phase EARLY_PHASE1	Recruiting	2024-07	China
Standardized Implementation and Quality Assessment System for Confocal Enteroscopy NCT07363291 · ClinicalTrials.gov ↗ · Confocal Enteroscopy, Quality Assessment System, Standardized Implementation	Observational	Recruiting	2025-06	China
A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients NCT03258320 · ClinicalTrials.gov ↗ · Prostate Cancer Patients	Phase 2/3	Recruiting	2015-01	China
A Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast NCT02897700 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 1	Recruiting	2013-01	China
Early Myocardial Dysfunction Helps Identify Severe Refractory Pediatric Lupus NCT07425730 · ClinicalTrials.gov ↗ · Systemic Lupus Erythematosus (SLE)	Observational	Recruiting	2026-02	China
Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia NCT05881265 · ClinicalTrials.gov ↗ · APL	Phase 2	Recruiting	2023-05	China
Overweight and Obesity and Puberty Development Cohort Study NCT04113070 · ClinicalTrials.gov ↗ · Precocious Puberty, Overweight and Obesity	Observational	Recruiting	2019-10	China
Genetics of Obesity in Chinese Youngs NCT01084967 · ClinicalTrials.gov ↗ · Obesity, Metabolic Syndrome	Observational	Recruiting	2009-03	China
Research on Early Prediction Model of Ischemic Cerebrovascular Disease Based on Artificial Intelligence Technology. NCT06978348 · ClinicalTrials.gov ↗ · Ischemic Cerebrovascular Disease, Artificial Intelligence, Prediction Model	Observational	Recruiting	2025-05	China
Neoadjuvant Adebrelimab and Chemotherapy in High-rish ER+/HER2- BC NCT06500208 · ClinicalTrials.gov ↗ · Breast Cancer Drug: Adebrelimab	Phase 2	Recruiting	2024-11	China
Clinical Evaluation of Non-invasive Blood Glucose Meter NCT06796322 · ClinicalTrials.gov ↗ · Diabetes Mellitus	Not applicable	Recruiting	2025-01	China
Magnetic Seizure Therapy for Psychotic Disorders NCT06581302 · ClinicalTrials.gov ↗ · Psychotic Disorders	Not applicable	Recruiting	2024-09	China
GzmB-PET/CT to Evaluate Neoadjuvant Therapy Efficacy in Breast Cancer NCT06725940 · ClinicalTrials.gov ↗ · Breast Cancer Invasive	Observational	Recruiting	2024-11	China
Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Malignancies NCT05991908 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, Myelodysplastic Syndromes Drug: Fludarabine and Busulfan	Phase 3	Recruiting	2023-10	China
Early De-escalation of Empirical Antibiotics Treatment for Neutropenic Fever NCT04270786 · ClinicalTrials.gov ↗ · Safety Issues	Not applicable	Recruiting	2020-01	China
Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients NCT05069857 · ClinicalTrials.gov ↗ · Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1 Drugs: Apatinib, Camrelizumab	Phase 2	Recruiting	2021-09	China
Multicenter, Phase II Clinical Study of Sacituzumab Tirumotecan (Sac-TMT) in Combination With KL-A167 for Neoadjuvant Treatment of Triple-Negative Breast Cancer NCT07371208 · ClinicalTrials.gov ↗ · Breast Cancer Drug: Sacituzumab tirumotecan	Phase 2	Recruiting	2025-12	China
Phage II Trial of Stathmin as Predictive Biomarker for TPF Induction Chemotherapy in OSCC NCT03326947 · ClinicalTrials.gov ↗ · Neoplasm Neck	Phase 2	Recruiting	2018-01	China
Support System Design for Adolescent Scoliosis Orthosis Wear NCT07574229 · ClinicalTrials.gov ↗ · Adolescent Idiopathic Scoliosis (AIS), Adherence	Not applicable	Recruiting	2026-02	China
A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer NCT02889666 · ClinicalTrials.gov ↗ · Recurrent Non-small Cell Lung Cancer Drugs: Carboplatin, Cisplatin, Docetaxel	Phase 1	Recruiting	2008-01	China
Atrophic Gastritis Predicts the Risk of Gastric Cancer NCT06203327 · ClinicalTrials.gov ↗ · Atrophic Gastritis	Observational	Recruiting	2023-12	China
An Early Clinical Trial to Evaluate VGN-R09b for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency. NCT05765981 · ClinicalTrials.gov ↗ · Aromatic L-amino Acid Decarboxylase (AADC) Deficiency Drug: VGN-R09b	Phase EARLY_PHASE1	Recruiting	2023-01	China
Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC NCT05125055 · ClinicalTrials.gov ↗ · Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1	Phase 2/3	Recruiting	2021-10	China
ctDNA in HER2+ EBC Neoadjuvant Treatment NCT07335081 · ClinicalTrials.gov ↗ · Breast Cancer Drugs: Docetaxel, Pertuzumab, Pyrotinib	Phase 2	Recruiting	2024-02	China
Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia NCT06607419 · ClinicalTrials.gov ↗ · B-Cell Lymphoblastic Leukemia Drug: Blinatumomab	Phase 2/3	Recruiting	2024-05	China
A Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes Mellitus NCT07303803 · ClinicalTrials.gov ↗ · MASH - Metabolic Dysfunction-Associated Steatohepatitis, T2DM (Type 2 Diabetes Mellitus) Drugs: Chiglitazar, Vitamin E	Phase 2	Recruiting	2026-01	China
Oral Health, Saliva Bacteria, and Disease Activity in Children With JIA: A Cross-Sectional Study. NCT07799831 · ClinicalTrials.gov ↗ · Juvenile Idiopathic Arthritis	Observational	Recruiting	2026-07	China
Prospective National Multi-center Registry of Obstructive Sleep Apnea Syndrome in Hypertensive Patients in China NCT05735444 · ClinicalTrials.gov ↗ · Hypertension, Obstructive Sleep Apnea	Observational	Recruiting	2023-01	China
Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer NCT07393425 · ClinicalTrials.gov ↗ · HER2 + Breast Cancer Drugs: Pertuzumab, Pyrotinib, Trastuzumab	Phase 2	Recruiting	2026-02	China
Treatment of Advanced Endocrine Tumor With Iindividualized mRNA Neoantigen Vaccine (mRNA-0523-L001) NCT06141369 · ClinicalTrials.gov ↗ · Adrenal Cortical Carcinoma, Medullary Thyroid Cancer, Thymic Neuroendocrine Carcinoma	Not applicable	Recruiting	2024-01	China
Precise Diagnosis, Treatment and Prognostic Evaluation of Complicated Adrenal Tumor Diseases NCT04529629 · ClinicalTrials.gov ↗ · Complicated Adrenal Tumor Diseases	Observational	Recruiting	2021-08	China
Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment Anti-thymoglobin as Graft Versus Host Disease Prophylaxis in Alternative Donor Peripheral Stem Cell Transplantation NCT06705062 · ClinicalTrials.gov ↗ · Allogeneic Hematopoietic Cell Transplant, Graft Versus Host Disease	Phase 3	Recruiting	2025-01	China
Shanghai Clinical Cohort - Adrenal Disease NCT07191951 · ClinicalTrials.gov ↗ · Adrenal Disease	Observational	Recruiting	2025-07	China
CS-121 APOC3 Base Editing in Children and Adolescents With Hyperchylomicronemia NCT07371767 · ClinicalTrials.gov ↗ · Hyperchylomicronemia Drug: CS-121	Phase EARLY_PHASE1	Recruiting	2026-01	China
Conditioning Regimen of Melphalan-busulfan and Fludarabine: a Randomized Study of Different Dose of Melphalan NCT06829472 · ClinicalTrials.gov ↗ · Toxicities, Survivorship Drug: Melphalan	Phase 3	Recruiting	2023-12	China
Reduced MBF Regimen for Patients >=55 Years With Myeloid Malignancies NCT05436561 · ClinicalTrials.gov ↗ · Disease-free Survival	Phase 2	Recruiting	2022-06	China
Short-course Trastuzumab, Pertuzumab with Taxanes in the Adjuvant Treatment of Early HER2-positive Breast Cancer NCT05891561 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Recruiting	2023-11	China
Multi-center Randomized Controlled Clinical Study of Shenling Baishu Granule to Prevent the Recurrence of Low-risk Colorectal Adenoma NCT06930157 · ClinicalTrials.gov ↗ · Low-risk Colorectal Adenoma	Phase 4	Recruiting	2025-11	China
The Diabetic Retinopathy Screening, Prevention and Control Program NCT04240652 · ClinicalTrials.gov ↗ · Diabetic Retinopathy	Observational	Recruiting	2018-06	China
Evaluation of the Safety, Tolerability, and Efficacy of LE051 in Patients With Duchenne Muscular Dystrophy NCT06900049 · ClinicalTrials.gov ↗ · Duchenne Muscular Dystrophy (DMD)	Phase EARLY_PHASE1	Recruiting	2024-10	China
Renal Artery Fibromuscular Dysplasia Registry NCT05363748 · ClinicalTrials.gov ↗ · Renal Artery Fibromuscular Dysplasia	Observational	Recruiting	2021-10	China
Doxycycline for Helicobacter Pylori Rescue Treatment NCT05874570 · ClinicalTrials.gov ↗ · Helicobacter Pylori Infection Drugs: Bismuth potassium citrate, Doxycycline, Esomeprazole	Phase 4	Recruiting	2023-06	China
Cyclin D1 Based TPF Induction Chemotherapy for Oral Squamous Cell Carcinoma Patients at Clinical N2 Stage NCT02290145 · ClinicalTrials.gov ↗ · Mouth Neoplasms, Carcinoma, Squamous Cell	Phase 2	Recruiting	2016-12	China
XP-005 Personalized Vaccine Alone or in Combination With Toripalimab for the Prevention of Relapse After Remission in Acute Myeloid Leukemia NCT06980155 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia Drug: Personalized neoantigen tumor vaccine	Phase EARLY_PHASE1	Recruiting	2025-05	China
Atherosclerotic Cardiovascular Risk in Childhood and Teen-age Onset Diabetes NCT05294653 · ClinicalTrials.gov ↗ · Atherosclerotic Cardiovascular Disease, Childhood Diabetes Mellitus, Juvenile Diabetes	Observational	Not yet open	2022-06	China
Circadian-Synchronized Breast Milk Feeding and Sleep in Preterm Infants: A Multicenter Randomized Controlled Trial NCT07645677 · ClinicalTrials.gov ↗ · Preterm Infant, Sleep	Not applicable	Not yet open	2026-09	China
PD-1 Antibody and JAK1 Inhibitor for Newly Diagnosed Pediatric Hodgikin's Lympoma NCT07641010 · ClinicalTrials.gov ↗ · Hodgkin Lymphoma Drug: PD-1	Phase 1/2	Not yet open	2026-06	China
Multi-omics Study of Peritoneal Dialysis Effluent to Explore Biomarkers of Peritoneal Fibrosis NCT07208513 · ClinicalTrials.gov ↗ · Peritoneal Dialysis, Peritoneal Fibrosis	Observational	Not yet open	2025-10	China
Evaluation of the Efficacy and Safety of Magnetically-controlled Capsule Gastroscopy for Postoperative Assessment in Elderly Patients and Patients With Underlying Diseases NCT06029608 · ClinicalTrials.gov ↗ · Evaluation,Efficacy,Safety	Observational	Not yet open	2025-11	China
Prospective Study Evaluate the Timing of Empirical Treatment for Carbapenem-resistant Bacterials (CROEAT Study) NCT07047352 · ClinicalTrials.gov ↗ · Carbapenem-resistant Enterobacterales, Neutropenia, Hematological Malignancies	Not applicable	Not yet open	2025-08	China
Standardized Antihypertensive Treatment Protocol NCT06790927 · ClinicalTrials.gov ↗ · Hypertension	Not applicable	Not yet open	2025-02	China
Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T-Cell Lymphoma NCT07535762 · ClinicalTrials.gov ↗ · Peripheral T-Cell Lymphoma (PTCL NOS), Nodal T-follicular Helper Cell Lymphoma, Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative) Drugs: Aclarubicin, Cyclophosphamide, Prednisone	Phase 2	Not yet open	2026-03	China
Electronic Blood Pressure Monitor for Atrial Fibrillation Detection NCT06931288 · ClinicalTrials.gov ↗ · Atrial Fibrillation (AF)	Not applicable	Not yet open	2025-05	China
Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma NCT07535710 · ClinicalTrials.gov ↗ · Cutaneous T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma, Relapsed, Sezary Syndrome Drugs: Aclarubicin, Cyclophosphamide, Prednisone	Phase 1/2	Not yet open	2026-03	China
Identification of Pathogenic Bacteria of Diabetes Foot Ulcer NCT06777810 · ClinicalTrials.gov ↗ · Diabetic Foot Disease, Diabetic Foot Ulcer, Diabetes	Observational	Not yet open	2025-01	China
Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia NCT07486726 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia (AML), Relapse Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia (AML) Drugs: Aclarubicin, Azacitidine, Venetoclax	Phase 1/2	Not yet open	2026-03	China
AI-Assisted Real-Time Endoscopic Characterization of Diminutive Colorectal Polyps in Non-Academic Hospitals NCT07362524 · ClinicalTrials.gov ↗ · Colorectal Polyps	Not applicable	Not yet open	2026-02	China
National Multicenter Registry for Pediatric End-Stage Heart Failure in China NCT06927440 · ClinicalTrials.gov ↗ · Heart Failure, Children	Observational	By invitation	2023-12	China
Organoid-based Sensitivity-guided Chemotherapy for Advanced / Refractory Pediatric Tumors NCT07528079 · ClinicalTrials.gov ↗ · Soft Tissue Sarcoma, Child	Not applicable	By invitation	2026-04	China
Intensive Management of Blood Pressure and Cholesterol in Elderly Chinese With Hypertension and Atrial Fibrillation NCT04111419 · ClinicalTrials.gov ↗ · Atrial Fibrillation, Hypertension Drug: Allisartan Isoproxil	Phase 4	Active, closed	2020-07	China
A Randomized Controlled Trial of Robotic Support for Enhanced Later Life (RoSELL) NCT07102017 · ClinicalTrials.gov ↗ · Loneliness, Well-Being, Psychological, Depression - Major Depressive Disorder	Not applicable	Active, closed	2025-05	China
A Clinical Study for the Treatment of Pediatric and Adolescent Patients With Type 1 Gaucher Disease NCT06528080 · ClinicalTrials.gov ↗ · Gaucher Disease	Phase EARLY_PHASE1	Active, closed	2024-08	China
Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast Cancer NCT02455141 · ClinicalTrials.gov ↗ · Breast Neoplasm	Phase 3	Active, closed	2016-03	China
Predictive Analysis of Diabetic Foot Ulcer NCT06768554 · ClinicalTrials.gov ↗ · Diabetic Foot Ulcer (DFU), Diabetic Foot Disease, Diabetes	Observational	Active, closed	2024-10	China
Open, Randomized Crossover Study on PK, PD, Biopotency, and Bioavailability of Insulin Capsules in Healthy Chinese Males NCT06519604 · ClinicalTrials.gov ↗ · Diabete Mellitus Drug: Human Insulin	Phase 1	Active, closed	2024-07	China
Gamified Digital Balance Assessment NCT07088848 · ClinicalTrials.gov ↗ · Disease Prevention	Not applicable	Active, closed	2025-04	China
Decreasing Risk of Psychosis by Sulforaphane (DROPS Trial) NCT03932136 · ClinicalTrials.gov ↗ · Clinical High Risk Syndrome of Psychosis	Phase 3	Active, closed	2019-07	China
Phase II Study of Sonrotoclax Combined With Chemotherapy in the Treatment of Newly Diagnosed Acute Myeloid Leukemia NCT06497062 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 2	Active, closed	2024-10	China
MRD in High-risk EBC NCT06566729 · ClinicalTrials.gov ↗ · Breast Cancer	Observational	Active, closed	2023-06	China
Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer NCT04398914 · ClinicalTrials.gov ↗ · Breast Cancer Invasive Drugs: Nab-paclitaxel, Pertuzumab, Pyrotinib	Phase 2	Active, closed	2020-05	China
Intensive Diet and Physical Activity on Diabetes NCT03839667 · ClinicalTrials.gov ↗ · Type2 Diabetes, Life Style	Not applicable	Active, closed	2019-01	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Shanghai Jiao Tong University School of Medicine trials

38 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Conditions in Shanghai Jiao Tong University School of Medicine trials

106 conditions

Breast Cancer6 Hypertension3 Acute Myeloid Leukemia3Colorectal Polyps2Helicobacter Pylori Infection2Duchenne Muscular Dystrophy (DMD)2Breast Cancer Invasive2 Oral Squamous Cell Carcinoma2Neoadjvant Therapy2Anti-PD-12Diabetic Foot Disease2Diabetes2Autoimmune Hepatitis1Refractory Leukemia1Atrial Fibrillation1Breast Cancer Early Stage Breast Cancer (Stage 1-3)1Atherosclerotic Cardiovascular Disease1Childhood Diabetes Mellitus1Juvenile Diabetes1Colorectal Adenoma1Colorectal Cancer Control and Prevention1Gallbladder Carcinoma1Preterm Infant1Sleep1

By trial register

Register	Trials	Recruiting
Clinical trials in China	77	50

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Breast Cancer

Sponsor	Trials
Fudan University	48
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	21
Second Affiliated Hospital, Zhejiang University, School of Medicine	19
AstraZeneca	15
Shengjing Hospital	15
Pfizer	12
Sichuan Baili Pharmaceutical	12
Cancer Institute and Hospital, Chinese Academy of Medical Sciences	12
Hoffmann-La Roche	10
Ruijin Hospital	10

Sponsors with the most current trials registered for this condition.

Questions about Shanghai Jiao Tong University School of Medicine trials

How many clinical trials does Shanghai Jiao Tong University School of Medicine sponsor?

Shanghai Jiao Tong University School of Medicine is the lead sponsor of 77 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Shanghai Jiao Tong University School of Medicine trials recruiting?

Yes. 50 of its 77 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Shanghai Jiao Tong University School of Medicine testing?

Its current trials name 38 drugs and biologicals as interventions. The most frequent are Pertuzumab (4), Pyrotinib (4), Trastuzumab (4), Aclarubicin (3) and Docetaxel (3). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Shanghai Jiao Tong University School of Medicine clinical trials